Monte Rosa Therapeutics anticipates Q1 2025 clinical data from its Phase 1 study of MRT-6160, a VAV1-directed molecular glue degrader for immune-mediated conditions.
Monte Rosa Therapeutics and Novartis have entered an exclusive agreement to develop and commercialize VAV1 molecular glue degraders, including MRT-6160.
Novartis and Monte Rosa Therapeutics have entered into a global agreement to develop and commercialize VAV1 molecular glue degraders, including MRT-6160.
Novartis and Monte Rosa Therapeutics have entered into a global licensing agreement worth up to $2.1 billion to develop VAV1-directed molecular glue degraders.